Incyte | INCY - Net Income


Incyte reported $299.28M in Net Income for its fiscal quarter ending in December of 2025.





Net Income Change Date
Acadia Pharmaceuticals USD 273.57M 201.79M Dec/2025
Agenus USD -25.27M 20.59M Mar/2025
Agios Pharmaceuticals USD -108.04M 4.61M Dec/2025
Alnylam Pharmaceuticals USD 186.42M 64.66M Dec/2025
Amgen USD 1.33B 1.88B Dec/2025
BioCryst Pharmaceuticals USD -88.88M 74.85M Dec/2024
Biogen USD 466.5M 168.3M Sep/2025
BioMarin Pharmaceutical USD -46.57M 15.83M Dec/2025
Bristol-Myers Squibb USD 1.09B 1.11B Dec/2025
Eli Lilly USD 6.64B 1.05B Dec/2025
Exelixis USD 193.58M 8.73M Sep/2025
Gilead Sciences USD 2.18B 869M Dec/2025
Incyte USD 299.28M 124.89M Dec/2025
Ionis Pharmaceuticals USD -229M 100.39M Dec/2025
MacroGenics USD 16.82M 53.07M Sep/2025
Merck USD 2.96B 2.82B Dec/2025
Moderna USD -200M 625M Sep/2025
Nektar Therapeutics USD -37.06M 15.31M Sep/2024
Neurocrine Biosciences USD 209.5M 102M Sep/2025
Novartis USD 3.93B 96M Sep/2025
Novartis USD 3.93B 113M Sep/2025
Pfizer USD -1.65B 5.19B Dec/2025
PTC Therapeutics USD -134.96M 150.86M Dec/2025
Puma Biotechnology USD 20.32M 24.85M Sep/2024
Regeneron Pharmaceuticals USD 844.6M 615.4M Dec/2025
Sarepta Therapeutics USD -412.23M 232.28M Dec/2025
Ultragenyx Pharmaceutical USD -129M 51.41M Dec/2025
Vertex Pharmaceuticals USD 1.19B 108.2M Dec/2025